Prof Alistair Nichol (Dublin & Melbourne) discusses why the REMAP-CAP adaptive platform trial has chosen to investigate ivermectin, given the controversy surrounding this agent.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
